Biotech Act Commission estimates the cost of Biotech Act protections at €210 million per year A Commission Staff Working Document supporting the Biotech Act I presented in December shows that the estimated cost of an extension to supplementary protection certificates could exceed €210 million per year
Access to Medicine Cancer Leagues call for overhaul of EU drug pricing transparency rules A new report from the Association of European Cancer Leagues says the EU’s Transparency Directive is no longer fit for purpose and is worsening inequalities in access to cancer medicines
Access to Medicine MSF denied access to Gilead HIV-prevention drug Médecins Sans Frontières accuses Gilead Sciences of blocking access to its HIV-prevention drug lenacapavir.
